In vivo piperazine ring degradation in neuroleptic and antihistaminic drugs.
D000818:Animals; D001711:Biotransformation; D004285:Dogs; D005029:Ethylenediamines / Q000378:metabolism; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000378:metabolism*; D010546:Perphenazine / Q000008:administration & dosage; D010640:Phenothiazines / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage / Q000378:metabolism*; D011346:Prochlorperazine / Q000008:administration & dosage; D051381:Rats; D011919:Rats, Inbred Strains; D014149:Tranquilizing Agents / Q000378:metabolism*; D014268:Trifluoperazine / Q000008:administration & dosage
D005029:Ethylenediamines; D006634:Histamine H1 Antagonists; D010640:Phenothiazines; D010879:Piperazines; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D010546:Perphenazine; D005476:Fluphenazine; D011346:Prochlorperazine